

ABIOMED INC  
Form 4  
May 12, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See Instruction*  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**MINOGUE MICHAEL R**

(Last) (First) (Middle)

**C/O ABIOMED, INC., 22  
CHERRY HILL DRIVE**

(Street)

**DANVERS, MA 01923**

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
**ABIOMED INC [ABMD]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**05/08/2015**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)

President, CEO, Chairman

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock \$.01 par value	05/08/2015		M	42,202 A	\$ 11.27 374,674	D	
Common Stock \$.01 par value	05/08/2015		M	15,000 A	\$ 13.8 389,674	D	
Common Stock \$.01 par value	05/08/2015		S <sup>(5)</sup>	10,805 <sup>(5)</sup> D	\$ 64.1598 <sup>(6)</sup> 378,869	D	
Common Stock \$.01	05/08/2015		S <sup>(5)</sup>	12,129 <sup>(5)</sup> D	\$ 366,740 65.1294	D	

par value					(7)		
Common					\$		
Stock \$.01	05/08/2015	S <sup>(5)</sup>	6,372 <sub>(5)</sub>	D	66.3304 <sub>(8)</sub>	360,368	D
par value							
Common					\$		
Stock \$.01	05/08/2015	S <sup>(5)</sup>	16,266 <sub>(5)</sub>	D	67.3336 <sub>(9)</sub>	344,102	D
par value							
Common					\$		
Stock \$.01	05/08/2015	S <sup>(5)</sup>	9,213 <sub>(5)</sub>	D	67.8776 <sub>(10)</sub>	334,889	D
par value							
Common					\$		
Stock \$.01	05/08/2015	S <sup>(5)</sup>	2,175 <sub>(5)</sub>	D	69.0306 <sub>(11)</sub>	332,714	D
par value							
Common					\$		
Stock \$.01	05/08/2015	S <sup>(5)</sup>	242 <sub>(5)</sub>	D	69.81 <sub>(12)</sub>	332,472	D
par value							

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) <u>(1)</u>	\$ 13.57							06/01/2007	06/01/2016	Common Stock	0
Stock Option (right to buy) <u>(1)</u>	\$ 11.27	05/08/2015		M		42,202		05/30/2008	05/30/2017	Common Stock	42,202
Stock Option	\$ 13.8	05/08/2015		M		15,000		05/23/2009 <u>(2)</u>	05/23/2018	Common Stock	15,000

(right to  
buy) (1)Stock  
Option  
(right to  
buy) (3)

\$ 18.63

06/15/2009<sup>(4)</sup>

08/13/2018

Common  
Stock

0

Stock  
Option  
(right to  
buy) (3)

\$ 5.86

05/28/2010<sup>(2)</sup>

05/28/2019

Common  
Stock

0

Stock  
Option  
(right to  
buy) (3)

\$ 5.86

05/28/2010<sup>(2)</sup>

05/28/2019

Common  
Stock

0

Stock  
Option  
(right to  
buy) (3)

\$ 10.03

06/03/2011<sup>(2)</sup>

06/03/2020

Common  
Stock

0

Stock  
Option  
(Right to  
Buy) (3)

\$ 22.44

05/22/2013<sup>(2)</sup>

05/22/2022

Common  
Stock

0

Stock  
Option  
(Right to  
Buy) (3)

\$ 23.15

05/14/2014<sup>(2)</sup>

05/14/2024

Common  
stock

0

Stock  
Option  
(right to  
buy) (3)

\$ 21.55

05/14/2015

05/14/2024

Common  
Stock

0

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MINOGUE MICHAEL R C/O ABIOMED, INC., 22 CHERRY HILL DRIVE DANVERS, MA 01923	X		President, CEO, Chairman	

## Signatures

/s/ Stephen C. McEvoy (by power of  
attorney)

05/12/2015

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Grant to reporting person of option to buy shares of Common Stock under the ABIOMED, Inc. 2000 Stock Incentive Plan.

(2) These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.

(3) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.

(4) These options become exercisable based on the achievement of certain performance milestones.

(5) Sale of common stock pursuant to reporting owner's 10b5-1 plan.

(6) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$63.6200 and \$64.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$64.6200 and \$65.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$65.6750 and \$66.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(9) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$66.7000 and \$67.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(10) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$67.7000 and \$68.6600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(11) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$68.7000 and \$69.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(12) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$69.7000 and \$69.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.